registration statement to Abbott for $1.4 billion.
See Note D— Business Combinations to our 2006 consolidated financial statements included in this annual report for further details on the Guidant acquisition and Abbott transaction.
During 2006, we received $145 million in proceeds from stock issuances related to our stock option and employee stock purchase plans as compared to $94 million in 2005.
Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the exercise and stock purchase patterns of employees.
We did not repurchase any of our common stock during 2006.
We repurchased approximately 25 million shares of our common stock at an aggregate cost of $734 million in 2005, and 10 million shares of our common stock at an aggregate cost of $360 million in 2004.
Since 1992, we have repurchased approximately 132 million shares of our common stock and we have approximately 12 million shares of our common stock held in treasury at year-end.
Approximately 37 million shares remain under our previous share repurchase authorizations.
Contractual Obligations and Commitments The following table provides a summary of certain information concerning our obligations and commitments to make future payments, which is in addition to our outstanding principal debt obligations as presented in the previous table.
See Note D— Business Combinations, Note F—Borrowings and Credit Arrangements and Note H—Leases to our 2006 consolidated financial statements included in this annual report for additional information regarding our business combinations, debt obligations and lease arrangements.
In accordance with U. S.  GAAP, our consolidated balance sheets do not reflect the obligations below that relate to expenses incurred in future periods.
## Table 0 ##
Certain of our business combinations involve the payment of contingent consideration.
See Note D—Business Combinations to our 2006 consolidated financial statements included in this annual report for the estimated maximum potential amount of future contingent consideration we could be required to pay associated with our business combinations.
Since it is not possible to estimate when, or even if, the acquired companies will reach their performance milestones or the amount of contingent consideration payable based on future revenues, the maximum contingent consideration has not been included in the table above.
Additionally, we may consider satisfying these commitments by issuing our stock or refinancing the commitments with cash, including cash obtained through the sale of our stock.
Certain of our equity investments give us the option to acquire the company in the future or may require us to make payments that are contingent upon the company achieving certain product development targets or obtaining regulatory approvals.
Since it is not possible to estimate when, or even if, we will exercise our option to acquire these companies or be required to make these contingent payments, we have not included future potential payments relating to these equity investments in the table above.
At December 31, 2006, we had outstanding letters of credit and bank guarantees of approximately $90 million, which primarily consisted of financial lines of credit provided by banks and collateral for workers’ compensation programs.
We enter these letters of credit and bank guarantees in the normal course of business.
As of December 31, 2006, we have not drawn upon the letters of credit or guarantees.
At this time, we do not believe we will be required to fund any amounts from the guarantees or letters of credit and, accordingly, we have not recognized a related liability in our financial statements as of December 31, 2006.
Our letters of credit and bank guarantees were immaterial at December 31, 2005.
Critical Accounting Policies We have adopted accounting policies to prepare our consolidated financial statements in conformity with U. S.  GAAP.
We describe these accounting polices in Note A—Significant Accounting Policies to our 2006 consolidated financial statements included in this annual report.
To prepare our consolidated financial statements in accordance with U. S.  GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent assets and liabilities at the date of our financial statements and the reported amounts of our revenue
related to our strategic alliances is generally limited to our equity investments and notes receivable associated with these alliances.
Equity investments in strategic alliances at December 31 consist of the following:
## Table 1 ##
As of December 31, 2006, we held investments totaling $95 million in four companies that we accounted for under the equity method.
Our ownership percentages in these companies range from approximately 21 percent to 28 percent.
The aggregate value of our equity method investments for which a quoted market price is available is approximately $125 million, for which the associated carrying value is approximately $77 million.
The aggregate difference between the carrying value of the investments and the value of our share in the net assets of the investee at the time that we determined that the investments qualified for equity method accounting was approximately $117 million.
This difference was attributable primarily to goodwill, which is not being amortized; purchased research and development, which was written-off at the time of application of the equity method of accounting; and intangible assets, which are being amortized over their estimated useful lives ranging from five to 20 years.
As of December 31, 2005, we held investments totaling $85 million in three companies that we accounted for under the equity method.
Our ownership percentages in these companies ranged from approximately 21 percent to 28 percent.
The aggregate value of our equity method investments for which a quoted market price was available was approximately $207 million, for which the associated carrying value was approximately $63 million.
The aggregate difference between the carrying value of the investments and the value of our share in the net assets of the investee at the time that we determined that the investments qualified for equity method accounting was approximately $70 million.
This difference is attributable primarily to goodwill, and intangible assets, which are being amortized over their estimated useful lives ranging from five to 20 years.
We regularly review our strategic investments for impairment indicators.
Based on this review, we recorded other-than-temporary impairments of approximately $78 million in 2006 related to cost method investments, the most significant impairment related to the termination of a gene therapy trial being conducted by one of our portfolio companies.
This trial was suspended in March 2006 and patient enrollment was terminated in April 2006.
The remaining carrying value of these cost method investments at December 31, 2006 was $49 million.
We determined there was no impairment on the remaining $306 million of our cost method investments.
As of December 31, 2006, we recorded other-than-temporary impairments of $4 million associated with certain of our available-for-sale investments.
As of December 31, 2006, we had six available-forsale investments in an unrealized loss position.
The duration of the unrealized loss was less than 12 months for each investment.
The aggregate carrying value of the investments was $87 million and the aggregate unrealized loss was $10 million.
We do not consider these investments to be other-than-temporarily impaired at December 31, 2006 due to the duration of the unrealized loss position and our ability and intent to hold the investments for a reasonable period sufficient for a recovery of the unrealized loss.
We recorded other-than-temporary impairments of $10 million in 2005 associated with certain cost method investments.
The remaining carrying value of these investments at December 31, 2005 was $16 million.
We determined there were no impairment indicators present for the remaining $350 million of our cost method investments.
We recorded other-than-temporary impairments of $3 million associated with certain of our available-for-sale investments.
As of December 31, 2005, we had two available-for-sale investments with an aggregate carrying value of $10 million and unrealized loss position of $4 million.
The duration of the unrealized loss position was less than 12 months.
We did not consider this investment to be other-than-temporarily impaired at December 31, 2005 due to the duration of the impairment and our ability and intent to hold the investment for a reasonable period sufficient for a forecasted recovery of the unrealized loss.
In addition, during 2005, we wrote-off our $24 million investment in Medinol, Ltd.  We canceled our equity investment in conjunction with the litigation settlement with Medinol.
The write-down of the Medinol investment is included in litigation-related charges in our consolidated statements of operations.
endovascular solutions businesses acquired by Abbott those services, rights, properties and assets of Guidant that were not included in the assets purchased by Abbott and that are reasonably required by Abbott to enable them to conduct the Guidant vascular and endovascular solutions businesses substantially as conducted at the time of the Abbott transaction closing; and (ii) Abbott will provide or make available to us those services, rights, properties and assets reasonably required by Boston Scientific to enable it to conduct the business conducted by Guidant, other than the Guidant vascular and endovascular solutions businesses, in substantially the same manner as conducted as of the Abbott transaction closing, to the extent those services, rights, properties and assets were included in the assets purchased by Abbott.
These transition services are available at prices based on costs incurred in performing the services.
Many of these transition services agreements expire during 2007.
Purchase Price We have accounted for the acquisition of Guidant as a purchase under U. S.  GAAP.
Under the purchase method of accounting, we recorded the assets and liabilities of Guidant as of the acquisition date, at their respective fair values, and consolidated them with those of legacy Boston Scientific.
The purchase price is based upon preliminary estimates of the fair value of assets acquired and liabilities assumed.
We are in the process of gathering information to finalize our valuation of certain assets and liabilities, primarily the determination of amounts that may be paid as a result of assumed product liability claims.
We will finalize the purchase price allocation once we have the necessary information to complete our estimate, but generally no later than one year from the acquisition date.
The preparation of the valuation required the use of significant assumptions and estimates.
Critical estimates included, but were not limited to, future expected cash flows and the applicable discount rates as of the date of the acquisition.
We based these estimates on assumptions that we believed to be reasonable as of the date of the acquisition.
However, actual results may differ from these estimates.
The preliminary purchase price is as follows (in millions):
## Table 2 ##
The fair value of the Boston Scientific stock options exchanged for Guidant options was included in the purchase price due to the fact that the options were fully vested.
We estimated the fair value of these options using a BlackScholes option-pricing model.
We estimated the fair value of the stock options assuming no expected dividends and the following weighted-average assumptions:
## Table 3 ##
Preliminary Purchase Price Allocation The following chart summarizes the Guidant preliminary purchase price allocation (in millions):
## Table 4 ##
The deferred tax liabilities relate primarily to the tax impact of future amortization associated with the identified intangible assets acquired, which are not deductible for tax purposes.
We allocated the excess of the purchase price over the fair value of net tangible assets acquired to specific intangible asset categories as follows:
## Table 5 ##
ENTERGY LOUISIANA, LLC AND SUBSIDIARIES MANAGEMENT’S FINANCIAL DISCUSSION AND ANALYSIS Plan to Spin Off the Utility’s Transmission Business See the “Plan to Spin Off the Utility’s Transmission Business” section of Entergy Corporation and Subsidiaries Management’s Financial Discussion and Analysis for a discussion of this matter, including the planned retirement of debt and preferred securities.
Results of Operations Net Income 2011 Compared to 2010 Net income increased $242.5 million primarily due to a settlement with the IRS related to the mark-to-market income tax treatment of power purchase contracts, which resulted in a $422 million income tax benefit.
The net income effect was partially offset by a $199 million regulatory charge, which reduced net revenue, because a portion of the benefit will be shared with customers.
See Note 3 to the financial statements for additional discussion of the settlement and benefit sharing.2010 Compared to 2009 Net income decreased slightly by $1.4 million primarily due to higher other operation and maintenance expenses, a higher effective income tax rate, and higher interest expense, almost entirely offset by higher net revenue.
Net Revenue 2011 Compared to 2010 Net revenue consists of operating revenues net of: 1) fuel, fuel-related expenses, and gas purchased for resale, 2) purchased power expenses, and 3) other regulatory charges (credits).
Following is an analysis of the change in net revenue comparing 2011 to 2010.
## Table 6 ##
The mark-to-market tax settlement sharing variance results from a regulatory charge because a portion of the benefits of a settlement with the IRS related to the mark-to-market income tax treatment of power purchase contracts will be shared with customers, slightly offset by the amortization of a portion of that charge beginning in October 2011.
See Notes 3 and 8 to the financial statements for additional discussion of the settlement and benefit sharing.
The retail electric price variance is primarily due to a formula rate plan increase effective May 2011.
See Note 2 to the financial statements for discussion of the formula rate plan increase.

<table><tr><td></td><td colspan="6">Payments Due by Period</td><td></td></tr><tr><td>(in millions)</td><td>2007</td><td>2008</td><td>2009</td><td>2010</td><td>2011</td><td>Thereafter</td><td>Total</td></tr><tr><td>Operating leases</td><td>$61</td><td>$47</td><td>$24</td><td>$11</td><td>$5</td><td>$36</td><td>$184</td></tr><tr><td>Purchase obligations<sup>†</sup></td><td>182</td><td>1</td><td>1</td><td>1</td><td></td><td></td><td>185</td></tr><tr><td>Minimum royalty obligations</td><td>3</td><td>3</td><td>3</td><td>1</td><td>1</td><td>6</td><td>17</td></tr><tr><td>Interest payments<sup>††</sup></td><td>521</td><td>497</td><td>457</td><td>371</td><td>214</td><td>1,013</td><td>3,073</td></tr><tr><td></td><td>$767</td><td>$548</td><td>$485</td><td>$384</td><td>$220</td><td>$1,055</td><td>$3,459</td></tr></table>
<table><tr><td></td><td colspan="2">2006</td><td colspan="2">2005</td></tr><tr><td>(in millions)</td><td></td><td>Number of Strategic Investments</td><td></td><td>Number of Strategic Investments</td></tr><tr><td>Available-for-sale investments</td><td></td><td></td><td></td><td></td></tr><tr><td>Amortized cost</td><td>$120</td><td></td><td>$103</td><td></td></tr><tr><td>Gross unrealized gains</td><td>36</td><td></td><td>44</td><td></td></tr><tr><td>Gross unrealized losses</td><td>-10</td><td></td><td>-4</td><td></td></tr><tr><td>Fair value</td><td>$146</td><td>9</td><td>$143</td><td>5</td></tr><tr><td>Equity method investments</td><td></td><td></td><td></td><td></td></tr><tr><td>Cost</td><td>$123</td><td></td><td>$94</td><td></td></tr><tr><td>Equity in losses</td><td>-28</td><td></td><td>-9</td><td></td></tr><tr><td>Carrying value</td><td>$95</td><td>4</td><td>$85</td><td>3</td></tr><tr><td>Cost method investments</td><td></td><td></td><td></td><td></td></tr><tr><td>Carrying value</td><td>$355</td><td>68</td><td>$366</td><td>58</td></tr><tr><td></td><td>$596</td><td>81</td><td>$594</td><td>66</td></tr></table>
<table><tr><td>Cash portion of consideration</td><td>$14,527</td></tr><tr><td>Fair value of Boston Scientific common stock</td><td>12,514</td></tr><tr><td>Fair value of Boston Scientific options exchanged for Guidant stock options</td><td>450</td></tr><tr><td>Buyout of options for certain former employees</td><td>97</td></tr><tr><td></td><td>27,588</td></tr><tr><td>Other acquisition-related costs</td><td></td></tr><tr><td>Johnson & Johnson termination fee</td><td>705</td></tr><tr><td>Other direct acquisition costs</td><td>65</td></tr><tr><td></td><td>$28,358</td></tr></table>
<table><tr><td>Expected term (in years)</td><td>2.4</td></tr><tr><td>Expected volatility</td><td>30%</td></tr><tr><td>Risk-free interest rate</td><td>4.92%</td></tr><tr><td>Stock price on date of grant</td><td>$22.49</td></tr><tr><td>Weighted-average exercise price</td><td>$13.11</td></tr></table>
<table><tr><td>Cash</td><td>$6,708</td></tr><tr><td>Intangible assets subject to amortization</td><td>7,719</td></tr><tr><td>Goodwill</td><td>12,354</td></tr><tr><td>Other assets</td><td>2,255</td></tr><tr><td>Purchased research and development</td><td>4,169</td></tr><tr><td>Current liabilities</td><td>-1,803</td></tr><tr><td>Net deferred income taxes</td><td>-2,549</td></tr><tr><td>Other long-term liabilities</td><td>-495</td></tr><tr><td></td><td>$28,358</td></tr></table>
<table><tr><td></td><td>AmountAssigned(in millions)</td><td>Weighted Average Amortization Period(in years)</td><td>Risk-Adjusted Discount Rates used in Purchase Price Allocation</td></tr><tr><td>Amortizable intangible assets</td><td></td><td></td><td></td></tr><tr><td>Technology - core</td><td>$6,142</td><td>25</td><td>10%-16%</td></tr><tr><td>Technology - developed</td><td>885</td><td>6</td><td>10%</td></tr><tr><td>Customer relationships</td><td>688</td><td>15</td><td>10%-13%</td></tr><tr><td>Other</td><td>4</td><td>10</td><td>10%</td></tr><tr><td></td><td>$7,719</td><td>22</td><td></td></tr><tr><td>Goodwill</td><td>$12,354</td><td></td><td></td></tr><tr><td>Purchased research and development</td><td>4,169</td><td></td><td>13%-17%</td></tr></table>
<table><tr><td></td><td>Amount (In Millions)</td></tr><tr><td>2010 net revenue</td><td>$1,043.7</td></tr><tr><td>Mark-to-market tax settlement sharing</td><td>-195.9</td></tr><tr><td>Retail electric price</td><td>32.5</td></tr><tr><td>Volume/weather</td><td>11.6</td></tr><tr><td>Other</td><td>-5.7</td></tr><tr><td>2011 net revenue</td><td>$886.2</td></tr></table>

Question: What's the total amount of Amortized cost and Gross unrealized gains in 2006? (in million)
Answer: 156